Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

TrevogrumabInterpret the evidence

Why COURAGE reported lean mass and weight separately at 52 weeks

2 numbered sourcesSource years 2024, 2026

Peptides are short chains of amino acids connected by peptide bonds. They can carry signals between tissues. Trevogrumab is a larger protein called a monoclonal antibody, designed to block the muscle growth regulator myostatin. The 2026 sponsor report from COURAGE compared changes on the scale with changes in whole-body lean mass when the investigational antibody was added to semaglutide. [1, 2]

In the portion of the study described in the new report, two groups received trevogrumab with semaglutide and another group received semaglutide with a placebo for the antibody. Participants were followed for 52 weeks. The sponsor reported that adding trevogrumab did not meaningfully change total weight reduction in that portion of the trial. The estimated decreases in lean mass at 52 weeks were about 5.8% and 4.2% in the combination groups, compared with about 7.3% in the semaglutide control group. [1]

The same comparison at 26 weeks showed declines of 4.7% and 3.3% in the groups receiving the antibody, and 6.7% in the control group. The sponsor also described the results as a percentage of lean mass loss prevented relative to control. For example, the 4.2% and 7.3% decreases at week 52 are about 3.1 percentage points apart. Dividing that difference by the control group's 7.3% decrease gives roughly 42% less lean mass loss relative to that group. Both groups still had a decline from their own starting point. [1]

Lean mass includes skeletal muscle and other fat-free tissues. The two measures can therefore tell different stories. A group can lose a similar amount of total weight while the amount of measured lean tissue changes by a different amount. The report measured lean mass with a body scan called DXA. A scan can estimate how much lean tissue is present, but the scan result does not indicate whether a person can walk farther or perform daily tasks more easily. Those questions need measures of function. [1, 2]

The sponsor reported that 77% of participants receiving the antibody in this portion and 82% of those in its control group experienced at least one adverse event. Common events included nausea, constipation, diarrhea and vomiting. These are summaries of what happened in the studied groups; a comparison of all reported events does not establish which individual symptoms were caused by the antibody. [1]

These figures come from the sponsor’s report and apply to the specific 52-week groups it described. Other portions of COURAGE included different study assignments, including an arm with an additional antibody. Their findings belong to those separate comparisons. The registry identifies the endpoints and study arms, and its September 2026 update listed no posted results. The sponsor report provides interim access to the observed estimates while the evidence for physical function and broader clinical outcomes remains a separate question. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Trevogrumab

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.